{"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"groups":[{"description":"Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42","upperLimit":"80","value":"66"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Korea, Republic of"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Hong Kong"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Australia"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}